Thermo Fisher Scientific receives FDA EUA for monkeypox assay | CPT PPP Coverage
Cryptopolytech (CPT) Public Press Pass (PPP)
News of the Day COVERAGE
200000048 – World Newser
•| #World |•| #Online |•| #Media |•| #Outlet |
View more Headlines & Breaking News here, as covered by cryptopolytech.com
Thermo Fisher Scientific receives FDA EUA for monkeypox assay appeared on www.medicaldevice-network.com by Hasini Devarasetti.
Thermo Fisher Scientific has received emergency use authorization (EUA) for its Applied Biosystems TaqPath Monkeypox/Orthopox Virus DNA Kit from the US Food and Drug Administration (FDA).
The polymerase chain reaction (PCR) test has been designed for detecting non-variola Orthopox viruses, including the monkeypox virus, in nearly three-and-a-half hours.
It is developed to detect DNA from the monkeypox virus (clade I/II) and screen for non-variola Orthopoxviruses in human lesion swab samples collected from people suspected of monkeypox infection.
The company stated that positive test results indicate the presence of DNA from the monkeypox virus or other non-variola orthopoxviruses.
Clinicians need to correlate PCR results with patient history, as well as other diagnostic data for determining the status of the infection.
Thermo Fisher Scientific Genetic Testing Solutions senior medical director Manoj Gandhi said: “Ensuring that all US laboratories have access to monkeypox PCR testing is a critical part of the response to this public health emergency.
“This helps expedite the availability of results so that patients can receive the appropriate treatment quickly.
“Authorised testing also enables public health agencies to stay one step ahead of the virus by monitoring the viral spread and addressing affected populations accordingly.”
The regulatory approval of the TaqPath Monkeypox/Orthopox Virus DNA Kit reflects the company’s commitment to developing diagnostic tools to address the demanding public health emergencies as early as possible.
Last month, Thermo Fisher Scientific signed a definitive agreement to buy global speciality diagnostics company, The Binding Site Group, in a cash transaction valued at $2.6bn.
The Binding Site Group is engaged in the research, development, manufacture as well as distribution of assays used for detecting cancers and immune disorders.
FEATURED ‘News of the Day’, as reported by public domain newswires.
View ALL Headlines & Breaking News here.
Source Information (if available)
This article originally appeared on www.medicaldevice-network.com by Hasini Devarasetti – sharing via newswires in the public domain, repeatedly. News articles have become eerily similar to manufacturer descriptions.
We will happily entertain any content removal requests, simply reach out to us. In the interim, please perform due diligence and place any content you deem “privileged” behind a subscription and/or paywall.
CPT (CryptoPolyTech) PPP (Public Press Pass) Coverage features stories and headlines you may not otherwise see due to the manipulation of mass media.
First to share? If share image does not populate, please close the share box & re-open or reload page to load the image, Thanks!